---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-026895"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:17:04.481519+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Isoray Q1 FY2023 revenue down 33% to $1.72M; net loss widens to $4.07M

## Summary
- Revenue $1.72M vs $2.56M YoY; core prostate brachytherapy revenue fell 41%.
- Net loss $4.07M ($0.03 per share) vs $2.24M ($0.02) in prior year.
- Gross margin dropped to 24.1% from 40.1%; isotope supply disruption cited.
- Cash and equivalents $54.1M with no long-term debt; stockholders' equity $57.7M.
- Pending merger with Viewpoint Molecular Targeting noted; G&A rose 69% on deal costs.

## SEC filing metadata
- accession: 0001437749-22-026895
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774922026895/0001437749-22-026895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774922026895/isr20221109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-026895
- JSON: https://secwatch.observer/filing/0001437749-22-026895.json
- Plain text: https://secwatch.observer/filing/0001437749-22-026895.txt

## Key facts
- Earnings Releases
  Perspective Therapeutics, Inc. reported the first quarter of fiscal 2023 ended September 30, 2022 results: revenue $1.72 million, net income $4.07 million or ($0.03) per basic and diluted share.
  - Period: the first quarter of fiscal 2023 ended September 30, 2022
  - Revenue: $1.72 million
  - Net income: $4.07 million or ($0.03) per basic and diluted share
  - Result: reported results
  source text: Revenue for the first quarter of fiscal 2023 decreased 33% to $1.72 million versus $2.56 million in the prior year comparable period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774922026895/0001437749-22-026895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.